Rachid Bouchikh-El Jarroudi, Kolbe Roche Fernández, Ester Casas-Gimeno, Hugo González-Valdivia, Carlos Ignacio Ortez-González, David Roche, Joan Prat-Bartomeu, Sebastian Videla
{"title":"Blepharospasm management in Schwartz-Jampel syndrome: A systematic review.","authors":"Rachid Bouchikh-El Jarroudi, Kolbe Roche Fernández, Ester Casas-Gimeno, Hugo González-Valdivia, Carlos Ignacio Ortez-González, David Roche, Joan Prat-Bartomeu, Sebastian Videla","doi":"10.1177/11206721251348991","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundBlepharospasm is one of the most limiting symptoms in patients with Schwartz-Jampel syndrome and can affect early visual development, causing amblyopia and leading to disability. There is no consensus on the optimal management of blepharospasm in these patients. This systematic review aims to evaluate the current evidence for the appropriate management strategies for blepharospasm in Schwartz-Jampel syndrome.MethodsThis was a prospective register of systematic reviews (PROSPERO)-registered (CRD42024569495), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline-adherent systematic review. Databases searched include Medline (PubMed), Scopus, and Web of Science from any time to February 1st, 2025. All scientific manuscripts published discussing the management of blepharospasm in patients with Schwartz-Jampel syndrome were included. A novel therapeutic algorithm has been developed and proposed.ResultsFrom an initial number of 59 articles, 15 of them were included. No clinical trials nor observational studies were found. All these 15 articles were case series or case reports (quality of evidence: 4 or 5), involving 21 patients. A great heterogeneity in how to manage blepharospasm in Schwartz-Jampel syndrome was gathered. Therapeutic options included oral drugs (sodium channel blockers: carbamazepine, phenytoin, and procainamide), botulinum-toxin-A, and eyelid surgery (orbicularis myectomy). The management algorithm proposal is oral sodium channel blockers as the first option and eyelid surgery as the second option treatment. Botulinum-toxin-A might be considered a therapeutic step prior to surgery.ConclusionsThe published evidence regarding management strategies for blepharospasm in Schwartz-Jampel syndrome is scarce and of low quality. Since this nosology is a very rare disease, efforts should be promoted to conduct clinical research and a consensus document for the management of blepharospasm.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251348991"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721251348991","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BackgroundBlepharospasm is one of the most limiting symptoms in patients with Schwartz-Jampel syndrome and can affect early visual development, causing amblyopia and leading to disability. There is no consensus on the optimal management of blepharospasm in these patients. This systematic review aims to evaluate the current evidence for the appropriate management strategies for blepharospasm in Schwartz-Jampel syndrome.MethodsThis was a prospective register of systematic reviews (PROSPERO)-registered (CRD42024569495), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline-adherent systematic review. Databases searched include Medline (PubMed), Scopus, and Web of Science from any time to February 1st, 2025. All scientific manuscripts published discussing the management of blepharospasm in patients with Schwartz-Jampel syndrome were included. A novel therapeutic algorithm has been developed and proposed.ResultsFrom an initial number of 59 articles, 15 of them were included. No clinical trials nor observational studies were found. All these 15 articles were case series or case reports (quality of evidence: 4 or 5), involving 21 patients. A great heterogeneity in how to manage blepharospasm in Schwartz-Jampel syndrome was gathered. Therapeutic options included oral drugs (sodium channel blockers: carbamazepine, phenytoin, and procainamide), botulinum-toxin-A, and eyelid surgery (orbicularis myectomy). The management algorithm proposal is oral sodium channel blockers as the first option and eyelid surgery as the second option treatment. Botulinum-toxin-A might be considered a therapeutic step prior to surgery.ConclusionsThe published evidence regarding management strategies for blepharospasm in Schwartz-Jampel syndrome is scarce and of low quality. Since this nosology is a very rare disease, efforts should be promoted to conduct clinical research and a consensus document for the management of blepharospasm.
背景:眼睑痉挛是Schwartz-Jampel综合征患者最具局限性的症状之一,可影响早期视觉发育,引起弱视并导致残疾。对于这些患者眼睑痉挛的最佳治疗方法尚无共识。本系统综述旨在评估当前的证据,为适当的管理策略眼睑痉挛施瓦茨- jampel综合征。方法:这是一项前瞻性系统评价注册(PROSPERO)注册(CRD42024569495),系统评价和荟萃分析首选报告项目(PRISMA)遵循指南的系统评价。检索的数据库包括Medline (PubMed)、Scopus和Web of Science,从任何时间到2025年2月1日。所有发表的讨论Schwartz-Jampel综合征患者眼睑痉挛管理的科学手稿被纳入。一种新的治疗算法已经被开发和提出。结果从最初的59篇文章中,纳入15篇。未发现临床试验或观察性研究。这15篇文章均为病例系列或病例报告(证据质量:4或5),涉及21例患者。在如何处理Schwartz-Jampel综合征眼睑痉挛方面存在很大的异质性。治疗方案包括口服药物(钠通道阻滞剂:卡马西平、苯妥英和普鲁卡因酰胺)、肉毒杆菌毒素a和眼睑手术(睑轮匝肌切除术)。治疗算法建议以口服钠通道阻滞剂为第一选择,眼睑手术为第二选择。肉毒杆菌毒素a可能被认为是手术前的治疗步骤。结论已发表的关于Schwartz-Jampel综合征眼睑痉挛治疗策略的证据很少且质量较低。由于这种疾病是一种非常罕见的疾病,因此应努力开展临床研究并形成共识文件来处理眼睑痉挛。
期刊介绍:
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.